Interfering with the ERC1-LL5β interaction disrupts plasma membrane-Associated platforms and affects tumor cell motility.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
05
2023
accepted:
10
06
2023
medline:
14
7
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
epublish
Résumé
Cell migration requires a complex array of molecular events to promote protrusion at the front of motile cells. The scaffold protein LL5β interacts with the scaffold ERC1, and recruits it at plasma membrane-associated platforms that form at the front of migrating tumor cells. LL5 and ERC1 proteins support protrusion during migration as shown by the finding that depletion of either endogenous protein impairs tumor cell motility and invasion. In this study we have tested the hypothesis that interfering with the interaction between LL5β and ERC1 may be used to interfere with the function of the endogenous proteins to inhibit tumor cell migration. For this, we identified ERC1(270-370) and LL5β(381-510) as minimal fragments required for the direct interaction between the two proteins. The biochemical characterization demonstrated that the specific regions of the two proteins, including predicted intrinsically disordered regions, are implicated in a reversible, high affinity direct heterotypic interaction. NMR spectroscopy further confirmed the disordered nature of the two fragments and also support the occurrence of interaction between them. We tested if the LL5β protein fragment interferes with the formation of the complex between the two full-length proteins. Coimmunoprecipitation experiments showed that LL5β(381-510) hampers the formation of the complex in cells. Moreover, expression of either fragment is able to specifically delocalize endogenous ERC1 from the edge of migrating MDA-MB-231 tumor cells. Coimmunoprecipitation experiments show that the ERC1-binding fragment of LL5β interacts with endogenous ERC1 and interferes with the binding of endogenous ERC1 to full length LL5β. Expression of LL5β(381-510) affects tumor cell motility with a reduction in the density of invadopodia and inhibits transwell invasion. These results provide a proof of principle that interfering with heterotypic intermolecular interactions between components of plasma membrane-associated platforms forming at the front of tumor cells may represent a new approach to inhibit cell invasion.
Identifiants
pubmed: 37437062
doi: 10.1371/journal.pone.0287670
pii: PONE-D-23-13577
pmc: PMC10337942
doi:
Substances chimiques
ERC1 protein, human
0
PHLDB2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0287670Informations de copyright
Copyright: © 2023 Ribolla et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Curr Protoc Cell Biol. 2007 Jan;Chapter 10:Unit 10.9
pubmed: 18228495
Nat Cell Biol. 2014 Jun;16(6):561-73
pubmed: 24859005
Nucleic Acids Res. 2023 Jan 6;51(D1):D438-D444
pubmed: 36416266
J Mol Biol. 2022 Jan 15;434(1):167228
pubmed: 34487789
Curr Opin Cell Biol. 2011 Oct;23(5):597-606
pubmed: 21550788
Cell. 2009 Mar 6;136(5):823-37
pubmed: 19269363
Genes Chromosomes Cancer. 1999 Jun;25(2):97-103
pubmed: 10337992
J Cell Sci. 2014 Sep 1;127(Pt 17):3862-76
pubmed: 24982445
Sci Rep. 2018 Jan 18;8(1):1164
pubmed: 29348417
PLoS One. 2013 Aug 12;8(8):e72426
pubmed: 23951323
J Biol Chem. 2003 Jan 10;278(2):1328-35
pubmed: 12376540
Methods Enzymol. 1996;266:554-71
pubmed: 8743706
J Cell Biol. 2010 May 31;189(5):901-17
pubmed: 20513769
Structure. 2003 Nov;11(11):1453-9
pubmed: 14604535
Nat Rev Drug Discov. 2022 Jun;21(6):440-462
pubmed: 35292771
J Cell Biol. 2013 Aug 19;202(4):637-51
pubmed: 23940118
Cell Signal. 2007 Apr;19(4):817-24
pubmed: 17174070
J Cell Sci. 2009 Sep 15;122(Pt 18):3225-32
pubmed: 19690048
Sci Rep. 2019 Sep 19;9(1):13530
pubmed: 31537859
J Cell Biol. 2004 Nov 8;167(3):505-18
pubmed: 15534002
Neuron. 2012 Jul 12;75(1):11-25
pubmed: 22794257
Sci Rep. 2016 Sep 23;6:33653
pubmed: 27659488
Int J Cell Biol. 2012;2012:941292
pubmed: 22505938
Cancer Res. 2006 Mar 15;66(6):3034-43
pubmed: 16540652
Dev Cell. 2006 Jul;11(1):21-32
pubmed: 16824950
J Biol Chem. 2010 May 21;285(21):16155-65
pubmed: 20236936
Sci Signal. 2015 Mar 10;8(367):re1
pubmed: 25759479
Am J Physiol Cell Physiol. 2011 Apr;300(4):C723-42
pubmed: 21209361
Dev Cell. 2013 Oct 28;27(2):145-160
pubmed: 24120883
Neuron. 2004 Jun 24;42(6):913-26
pubmed: 15207236
J Biol Chem. 2010 Sep 3;285(36):27581-9
pubmed: 20587420
J Biol Chem. 2003 Oct 24;278(43):42377-85
pubmed: 12923177
Genes Cells. 2006 Jun;11(6):659-72
pubmed: 16716196
J Magn Reson B. 1995 Jul;108(1):94-8
pubmed: 7627436
Mol Biol Cell. 2007 Dec;18(12):5124-38
pubmed: 17898078
J Cell Biol. 2005 Apr 25;169(2):355-66
pubmed: 15851520
J Cell Sci. 2020 Apr 24;133(8):
pubmed: 32332092